Royalty Pharma (RPRX) Research & Development (2019 - 2026)
Royalty Pharma (RPRX) reported Research & Development of $39.8 million for Q1 2026, down 21.19% on a YoY basis from $50.5 million in Q1 2025, and down 21.19% sequentially from $50.5 million in Q4 2025.
Royalty Pharma (RPRX) Research & Development (2019 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 8 years of Research & Development data on file, last reported at $39.8 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 21.19% year-over-year to $39.8 million; the trailing twelve-month figure through Mar 2026 stood at $390.8 million (up 651.54% YoY), and the FY2025 full-year result was $452.0 million, up 22500.0% from the prior year.
- Research & Development declined to $39.8 million in Q1 2026, from $50.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $250.0 million in Q2 2025 to a low of $500000.0 in Q1 2023.
- A 5-year average of $39.6 million and a median of $25.5 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development sank 99.5% in 2023 and surged 49900.0% in 2025, its largest moves.
- Tracing RPRX's Research & Development over 5 years: stood at $50.5 million in 2022, then plunged by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then surged by 10000.0% to $50.5 million in 2025, then declined by 21.19% to $39.8 million in 2026.
- Business Quant data shows RPRX's Research & Development at $39.8 million in Q1 2026, $50.5 million in Q4 2025, and $50.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 39.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.80 Mn |
| Dec 31, 2025 | 50.50 Mn |
| Sep 30, 2025 | 50.50 Mn |
| Jun 30, 2025 | 250.00 Mn |
| Mar 31, 2025 | 50.50 Mn |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 50.50 Mn |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 50.49 Mn |
| Sep 30, 2022 | 25.50 Mn |
| Jun 30, 2022 | 606,000.00 |
| Mar 31, 2022 | 100.50 Mn |
| Dec 31, 2021 | 103.78 Mn |
| Sep 30, 2021 | 90.50 Mn |
| Jun 30, 2021 | 3.12 Mn |